Physician profile
Deepa Philip
NPI 1659614105
$4,046.55
in general payments reported to CMS, 2019-2025
33 companies · $2,764 in 2025
The $2,764 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2024: $1,022 · 2025: $2,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,743 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,743.48 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $371.58 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $296.05 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $291.04 | 2024-2025 | Evenity, Tepezza, Prolia |
| Madrigal Pharmaceuticals | $278.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Corcept Therapeutics | $231.36 | 2024-2025 | Korlym |
| Medtronic, INC. | $222.51 | 2024-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $220.23 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $146.32 | 2025 | Yorvipath |
| Dexcom, INC. | $145.46 | 2024-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $143.71 | 2024-2025 | Tymlos |
| Medtronic Minimed, INC. | $135.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.62 | 2024-2025 | Jardiance |
| Abbott Laboratories | $134.68 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $124.89 | 2019 | |
| Lilly USA, LLC | $112.04 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $108.16 | 2024-2025 | Crysvita |
| Beta Bionics, INC. | $106.72 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $101.00 | 2024-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $92.28 | 2024-2025 | |
| Mannkind Corporation | $89.81 | 2025 | |
| Sequel Med Tech, LLC | $89.24 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $78.66 | 2024-2025 | Strensiq |
| Insulet Corporation | $72.28 | 2024-2025 | Omnipod |
| Cequr Corporation | $70.78 | 2024-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $48.74 | 2025 | Unithroid |
| Acella Pharmaceuticals, LLC | $42.50 | 2025 | NP Thyroid 60 |
| Antares Pharma, INC. | $39.78 | 2024 | Xyosted |
| Globus Medical, INC. | $27.47 | 2025 | Omnia |
| Astellas Pharma US INC | $24.77 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $18.92 | 2025 | |
| Recordati_rare_diseases_inc. | $16.34 | 2025 | Isturisa |
| Currax Pharmaceuticals LLC | $15.11 | 2025 | Onzetra Xsail, Contrave |
| Averitas Pharma INC. | $14.32 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Philip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.